Abstract:Emerging evidence suggests the critical roles of N6-methyladenosine (m6A) RNA modification in tumorigenesis and tumor progression. However, the role of m6A in non-small cell lung cancer (NSCLC) is still unclear. This study aimed to explore the role of the m6A demethylase fat mass and obesity-associated protein (FTO) in the tumor metastasis of NSCLC. A human m6A epitranscriptomic microarray analysis was used to identify downstream targets of FTO. Quantitative real-time PCR (qRT‒PCR) and western blotting were employed to evaluate the expression levels of FTO and FAP in NSCLC cell lines and tissues. Gain-of-function and loss-of-function assays were conducted in vivo and in vitro to assess the effects of FTO and FAP on NSCLC metastasis. M6A-RNA immunoprecipitation (MeRIP), RNA immunoprecipitation (RIP), luciferase reporter assays, and RNA stability assays were used to explore the mechanism of FTO action. Co-immunoprecipitation (co-IP) assays were used to determine the mechanism of FAP in NSCLC metastasis. FTO was upregulated and predicted poor prognosis in patients with NSCLC. FTO promoted cell migration and invasion in NSCLC, and the FAK inhibitor defactinib (VS6063) suppressed NSCLC metastasis induced by overexpression of FTO. Mechanistically, FTO facilitated NSCLC metastasis by modifying the m6A level of FAP in a YTHDF2-dependent manner. Moreover, FTO-mediated metastasis formation depended on the interactions between FAP and integrin family members, which further activated the FAK signaling. Our current findings provided valuable insights into the role of FTO-mediated m6A demethylation modification in NSCLC metastasis. FTO was identified as a contributor to NSCLC metastasis through the activation of the FAP/integrin/FAK signaling, which may be a potential therapeutic target for NSCLC. Emerging evidence suggests the crucial roles of N6-methyladenosine (m6A) RNA modification in tumorigenesis and progression. Nonetheless, the role of m6A in NSCLC remains unclear. The purpose of this study was to investigate the role of m6A demethylase fat mass and obesity-associated protein (FTO) in the tumor metastasis of non-small cell lung cancer (NSCLC). Results illustrated that FTO was upregulated and predicted poor prognosis in NSCLC patients. FTO promoted cell migration and invasion in NSCLC, and the FAK inhibitor defactinib (VS6063) suppressed NSCLC metastasis induced by overexpression of FTO. Mechanistically, FTO facilitated NSCLC metastasis by modifying the m6A level of FAP in a YTHDF2-dependent manner. Moreover, FTO-mediated metastasis formation depended on the interactions between FAP and integrin family members, which further activated the FAK signaling. Our current findings provided valuable insights into the role of FTO-mediated m6A demethylation modification in NSCLC metastasis. FTO was identified as a contributor to NSCLC metastasis through the activation of the FAP/integrin/FAK signaling, which may be a potential therapeutic target for NSCLC.

FTO elicits tumor neovascularization in cancer-associated fibroblasts through eliminating m 6 A modifications of multiple pro-angiogenic factors

FTO Elicits Tumor Neovascularization in Cancer-Associated Fibroblasts Through Eliminating M6a Modifications of Multiple Pro-Angiogenic Factors

SPI1-induced Downregulation of FTO Promotes GBM Progression by Regulating Pri-Mir-10a Processing in an M6a-Dependent Manner

FTO regulates ocular angiogenesis via m6A-YTHDF2-dependent mechanism

N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1 alpha signalling axis

RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner

The m6A Demethylase FTO Promotes Esophageal Cancer Progression Through YTHDF1-Dependent Posttranscriptional Silencing of AKT3

The RNA N6-methyladenosine demethylase FTO regulates ATG5 to inhibit malignant progression of uveal melanoma

The m6A eraser FTO facilitates proliferation and migration of human cervical cancer cells

FTO Facilitates Cancer Metastasis by Modifying the M 6 A Level of FAP to Induce Integrin/fak Signaling in Non-Small Cell Lung Cancer

FTO Promotes Clear Cell Renal Cell Carcinoma Progression Via Upregulation of PDK1 Through an M6a Dependent Pathway

FTO promotes the progression of bladder cancer via demethylating m6A modifications in PTPN6 mRNA

FTO regulates adipogenesis by controlling cell cycle progression via mA-YTHDF2 dependent mechanism.

WNT/β-catenin-suppressed FTO expression increases m 6 A of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis

WNT/β-catenin-suppressed FTO expression increases m6A of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis

FTO Facilitates Lung Adenocarcinoma Cell Progression by Activating Cell Migration Through Mrna Demethylation

m6A demethylase FTO promotes tumor progression via regulation of lipid metabolism in esophageal cancer

m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade

MiR-155 regulates m6A level and cell progression by targeting FTO in clear cell renal cell carcinoma

WNT/-catenin-suppressed FTO expression increases m<SUP>6</SUP>A of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis

Effect of demethyltransferase FTO on tumor progression